Ju Li
Impact in
Papers in
-
- CRISPR and Genetic Engineering 15
- RNA and protein synthesis mechanisms 9
- Muscle Physiology and Disorders 8
- RNA regulation and disease 6
- Advanced biosensing and bioanalysis techniques 6
-
- Lymphoma Diagnosis and Treatment 10
- Co-authors
- Remo Panaccione (4 shared papers)William J. Sandborn (4 shared papers)Paul F. Pollack (3 shared papers)Jeffrey D. Kent (3 shared papers)Paul Rutgeerts (3 shared papers)Robert Enns (1 shared paper)Jean–Frédéric Colombel (1 shared paper)Stefan Schreiber (1 shared paper)
- Journals
- Medical Physics (10 papers)Nature Communications (5 papers)Blood (3 papers)Nature Biotechnology (3 papers)Journal of Animal Science (3 papers)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Ju Li
96 papers receiving 4.6k citations
Ju Li's Hit Papers
Peers
Comparison fields: 5 of 148
- Genetics 2.3k
- Aging 98
- Epidemiology 939
- Immunology 476
- Business and International Management 50
Countries citing papers authored by Ju Li
This map shows the geographic impact of Ju Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ju Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ju Li more than expected).
Fields of papers citing papers by Ju Li
This network shows the impact of papers produced by Ju Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ju Li. The network helps show where Ju Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Ju Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 98 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial Hit paper breakdown → | 2006 | 1716 |
| 2 | Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab Hit paper breakdown → | 2007 | 760 |
| 3 | Glycosylase base editors enable C-to-A and C-to-G base changes Hit paper breakdown → | 2020 | 363 |
| 4 | 2014 | 319 | |
| 5 | 2006 | 122 | |
| 6 | 2009 | 105 | |
| 7 | 2013 | 99 | |
| 8 | 2017 | 84 | |
| 9 | 2021 | 56 | |
| 10 | 2024 | 51 | |
| 11 | 2002 | 48 | |
| 12 | 2014 | 43 | |
| 13 | 2006 | 38 | |
| 14 | 2011 | 37 | |
| 15 | 2011 | 36 | |
| 16 | 2018 | 36 | |
| 17 | 2023 | 35 | |
| 18 | 2009 | 34 | |
| 19 | 2019 | 33 | |
| 20 | 2013 | 29 |
About Ju Li
Ju Li is a scholar working on Molecular Biology, Pathology and Forensic Medicine, Genetics, Oncology and Radiation, having authored 98 papers that have together received 4.7k indexed citations. Recurring topics across this work include CRISPR and Genetic Engineering (15 papers), Lymphoma Diagnosis and Treatment (10 papers), RNA and protein synthesis mechanisms (9 papers), Muscle Physiology and Disorders (8 papers), Advanced Radiotherapy Techniques (8 papers), RNA regulation and disease (6 papers), Advanced biosensing and bioanalysis techniques (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). The work is most often cited by research in Genetics (2.3k citations), Aging (98 citations), Epidemiology (939 citations), Immunology (476 citations) and Business and International Management (50 citations). Ju Li has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Remo Panaccione, William J. Sandborn, Paul F. Pollack, Jeffrey D. Kent, Paul Rutgeerts, Robert Enns, Jean–Frédéric Colombel, Stefan Schreiber, Stephen B. Hanauer and Sally Johnson. Their work appears in journals such as Medical Physics, Nature Communications, Blood, Nature Biotechnology and Journal of Animal Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.